Search > HS
150 Participants NeededMy employer runs this trial

SPY072 for Hidradenitis Suppurativa

Recruiting at 35 trial locations
ST
Overseen BySKYLIGHT Trial Center
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Spyre Therapeutics, Inc.
Disqualifiers: More than 20 draining tunnels, others
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.

Who Is on the Research Team?

JF

Joshua Friedman, MD, PhD

Principal Investigator

Spyre Therapeutics, Inc.

Are You a Good Fit for This Trial?

This trial is for adults with moderate to severe hidradenitis suppurativa (HS) who are already receiving advanced standard treatments. Participants must meet certain health requirements and cannot join if they have conditions that could interfere with the study.

Inclusion Criteria

I have had Hidradenitis Suppurativa symptoms for at least 6 months.
I have hidradenitis suppurativa in at least 2 body areas, with one area being moderate or severe.
I have at least 5 abscesses or inflamed nodules now and at screening.
See 1 more

Exclusion Criteria

More than 20 draining tunnels at screening or Day 1
I have not needed surgery or drainage for hidradenitis suppurativa recently.
I have another skin or inflammatory condition that may affect my hidradenitis suppurativa assessment.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive SPY072 or placebo for 16 weeks

16 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

36 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • SPY072

Trial Overview

The study is testing a new medicine called SPY072 compared to a placebo in about 150 adults with HS. Participants are randomly assigned to receive either SPY072 or placebo for 16 weeks, and will be monitored afterward for safety and lasting effects.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Placebo Group

Group I: SPY072 + bimekizumabExperimental Treatment2 Interventions
Group II: Placebo + bimekizumabPlacebo Group2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Spyre Therapeutics, Inc.

Lead Sponsor

Trials
4
Recruited
270+

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.